The FDA in the USA has approved dupilumab
(Dupixent®) for children aged 6-11 years with moderate to severe atopic
dermatitis "whose disease is not adequately controlled with topical
prescription therapies or when those therapies are not advisable," For
children aged 6-11, the two available dupilumab doses in prefilled syringes are
given based on weight — 300 mg every 4 weeks for children between 15 to 29 kg
and 200 mg every 2 weeks for children 30 to 59 kg — following an initial
loading dose.
